343
Views
7
CrossRef citations to date
0
Altmetric
Notes

A new cyclolignan glycoside from the tubers of Pinellia ternata

, , , , , , , & show all
Pages 1097-1103 | Received 26 Jan 2015, Accepted 14 Apr 2015, Published online: 19 May 2015
 

Abstract

A new 2,7′-type cyclolignan glycoside, cyclolignanyingoside A (1), together with six known compounds (27) were isolated from the tubers of Pinellia ternata (Thunb.) Breit. The structure of 1 was elucidated on the basis of chemical and spectral analysis, including 1D, 2D NMR analyses, HR-ESI-MS, and CD spectrometry. The cytotoxic, antioxidant and tyrosinase-inhibiting activities of all the isolates were determined. However, all the isolates exhibited no activity on the selected cell lines (Hep-3B, Bcap-37, and MCF-7). In addition, compounds 13 and 7 exhibited strong 2,2′-azino-bis (3-ethylbenzothiazoline-6-sulphonic acid) free radical scavenging activity, and compounds 2 and 4 showed a moderate mushroom tyrsinase inhibitory activity.

Acknowledgements

Authors thank Mrs Wen Li. and Mr Yi Sha of Shenyang Pharmaceutical University for recording of NMR spectra.

Disclosure statement

No potential conflict of interest was reported by the authors.

Additional information

Funding

Financial supports from the National Natural Sciences Foundation of China (Nos 81130071 and 81373925) and Program for Liaoning Excellent Talents in University (LR2012034).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.